Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Thao977on Nov 18, 2021 6:53pm
158 Views
Post# 34143295

RE:RE:RE:New post on LinkedIn

RE:RE:RE:New post on LinkedIn We saw 2 very optimist person. They call it possible cure for cancer

Richard Beliveau 
In 35 years, he never saw something promising like it
For now, they didn't have surprise. Everything was like expected
It's a dream for a searcher
Fast track, very exceptionnal to have it
Sortilin was never investigated. We are the first


Paul L 
Agreed with DR Beliveau
Big Challenge. Financing !! Will need a lot of money but once clinical data will come, money will follow
US investor saw something very interresting in pre-clinical data.
---
Nothing new but it's good publicity. 
<< Previous
Bullboard Posts
Next >>